Brief: Affimed reports financial results for third quarter 2016
02/11/2016 11:30
Nov 2 (Reuters) - Affimed Nv AFMD.O
* Affimed nv says has decided to advance afm24, an
egfrwt/cd16a tandab, in solid tumors
* Affimed nv says affimed intends to provide an update on
afm24 program in first half of 2017
* Affimed reports financial results for third quarter 2016
* Q3 loss per share eur 0.31
* Q3 revenue eur 900,000 versus eur 1.2 million
* Q3 revenue view eur 2.4 million -- Thomson Reuters I/B/E/S
* Q3 earnings per share view eur -0.24 -- Thomson Reuters
I/B/E/S
Source text for Eikon: ID:nGNXNKNJPa
Further company coverage: AFMD.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Affimed NV
See all newsBrief: Affimed Announces Receipt Of Nasdaq Delisting Notice
Brief: Affimed Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Brief: Affimed Reports Positive Clinical Update On Afm24/Atezolizumab Combination Therapy
Brief: Affimed NV Files For Common Stock Offering Of Up To $20 Million - SEC Filing
Brief: Affimed NV Files For Mixed Shelf Offering Of Up To $20 Million